Sign inJoin waitlistJoin the waitlist

Justin Kline

Director, Lymphoma Program · University of Chicago Medical Center

Credentials: · · ·

History

Pritzker School of Medicine
Present
University of Chicago Medical Center
Present

Hematology and Medical Oncology
University of Chicago Medical Center
2004–2007
Internal Medicine
University of Chicago Medical Center
2001–2004
University of Chicago Division of the Biological Sciences, The Pritzker School of Medicine
1997–2001

Research

Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells
The Journal of Experimental Medicine · 2011 · 1,020 citations
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma
New England Journal of Medicine · 2018 · 972 citations
CD47 blockade triggers T cell-mediated destruction of immunogenic tumors
Nature Medicine · 2015 · 666 citations

Michael Bishop
34 papers
Peter Riedell
26 papers · 3 as a fellow
Sonali Smith
24 papers
Wendy Stock
24 papers
Andrew Artz
23 papers
Richard Larson
21 papers
Hongtao Liu
20 papers
Koen van Besien
20 papers · 4 as a resident
JS
James Stock
17 papers · 2 as a fellow
Olatoyosi Odenike
14 papers
Thomas Gajewski
14 papers
Lucy Godley
13 papers

Grants

Integrative Approach to Identify Genomic Features That Shape the Immune Landscape and Predict Immunotherapy Response in Diffuse Large B Cell Lymphoma
National Cancer Institute · R01
Contact PI · $1.5M · University of Chicago
2023–2028
Development of Antigen Multimers for CAR T Cell Detection and Functional Profiling
National Institute of Allergy and Infectious Diseases · R21
PI · $437.2K · University of Chicago
2023–2025
Characterization of a T Cell Dysfunctional State Induced in Mice with AML
National Cancer Institute · R01
Contact PI · $1.6M · University of Chicago
2012–2018
Homeostatic Proliferation and Regulatory T Cell Depletion as Cancer Immunotherapy
National Cancer Institute · K23
Contact PI · $649.2K · University of Chicago
2008–2013

Clinical trials

Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)
Principal investigator · Terminated · Phase 2
University of Chicago
2019–2024
Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma
Principal investigator · Active not recruiting · Phase 2
University of Chicago
2019–2027
Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation
Principal investigator · Completed · Early phase 1
University of Chicago
2017–2020
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Site PI · Recruiting · Phase 2
SWOG Cancer Research Network
2023–2029